• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket

    7/11/23 8:33:53 AM ET
    $ABOS
    $BTTX
    $CACO
    $CNEY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABOS alert in real time by email

    Gainers

    • CytoMed Therapeutics Limited (NASDAQ:GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday.
    • Better Therapeutics, Inc. (NASDAQ:BTTX) shares gained 51.1% to $1.36 in pre-market trading after the FDA approved the company's AspyreRx prescription-only digital therapeutic treatment to provide cognitive behavioral therapy to adult patients with type 2 diabetes.
    • Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares rose 42.2% to $0.1450 in pre-market trading after declining around 14% on Monday.
    • Trinity Place Holdings Inc. (NYSE:TPHS) gained 24.1% to $0.6790 in pre-market trading after declining around 15% on Monday.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares rose 20.8% to $0.54 in pre-market trading.
    • NanoViricides, Inc. (NYSE:NNVC) rose 19.9% to $1.69 in pre-market trading. NanoViricides reported effectiveness of antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with respiratory syncytial virus.
    • Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares climbed 18.2% to $5.86 in pre-market trading. Acumen Pharmaceuticals recently announced it will present topline results from a Phase 1 trial of its candidate ACI193 at the Alzheimer's Association International Conference in July.
    • CN Energy Group. Inc. (NASDAQ:CNEY) rose 15.6% to $0.2110 in pre-market trading after falling around 6% on Monday.
    • T2 Biosystems, Inc. (NASDAQ:TTOO) gained 14.5% to $0.1811 in pre-market trading after jumping around 37% on Monday.
    • Caravelle International Group (NASDAQ:CACO) shares gained 12.6% to $0.6190 in pre-market trading.

    Losers

    • DSS, Inc. (NYSE:DSS) fell 17.1% to $0.3002 in pre-market trading. DSS Wealth, Inc., a wholly owned subsidiary of DSS, Inc, named Daniel Lew as Chief Investment Officer and Portfolio Manager.
    • Viridian Therapeutics, Inc. (NASDAQ:VRDN) fell 14.4% to $20.99 in pre-market trading after announcing data from ongoing Phase 1/2 trial evaluating VRDN-001 in patients with chronic thyroid eye disease.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) fell 12.5% to $7.69 in pre-market trading as the company priced its underwritten public offering of 20,000,000 shares at $7.50 per share.
    • Jupiter Wellness, Inc. (NASDAQ:JUPW) fell 11.9% to $0.4845 in pre-market trading. Jupiter Wellness shares jumped over 50% on Monday after the company announced it has executed an Asset Purchase Agreement with GBB Drink Lab to acquire all operating assets including the "Safety Shot" rapid alcohol detox drink.
    • REE Automotive Ltd. (NASDAQ:REE) shares dropped 10.5% to $0.34 in pre-market trading. REE Automotive recently named Carlton Rose, former global president of fleet maintenance and engineering at UPS, to the company’s board of directors.
    • Tattooed Chef, Inc. (NASDAQ:TTCF) fell 10.1% to $0.1889 in pre-market trading after declining 19% on Monday. Tattooed Chef recently announced it intends to file for voluntary Chapter 11 Bankruptcy protection.
    • Journey Medical Corporation (NASDAQ:DERM) shares fell 9.2% to $2.58 in pre-market trading after climbing around 21% on Monday.
    • EZFill Holdings Inc. (NASDAQ:EZFL) fell 9.1% to $2.00 in pre-market. EzFill achieved another quarterly record for gallons delivered in the second quarter.
    • urban-gro, Inc. (NASDAQ:UGRO) shares fell 8.1% to $1.83 in pre-market trading after rising around 5% on Monday.
    • Ryvyl Inc. (NASDAQ:RVYL) fell 7.8% to $1.07 in pre-market trading after gaining over 5% on Monday.

     

    Now Read This: Market Volatility Increases Ahead Of Inflation Reports; S&P 500 Settles Higher

    Get the next $ABOS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABOS
    $BTTX
    $CACO
    $CNEY

    CompanyDatePrice TargetRatingAnalyst
    Iovance Biotherapeutics Inc.
    $IOVA
    2/25/2026$5.00Mkt Perform → Mkt Outperform
    Citizens
    NanoViricides Inc.
    $NNVC
    12/16/2025Buy
    Alliance Global Partners
    Viridian Therapeutics Inc.
    $VRDN
    12/10/2025$42.00 → $47.00Outperform
    Wedbush
    Viridian Therapeutics Inc.
    $VRDN
    12/3/2025Outperform
    William Blair
    Viridian Therapeutics Inc.
    $VRDN
    11/24/2025Buy
    Truist
    Viridian Therapeutics Inc.
    $VRDN
    8/25/2025$44.00Buy
    Jefferies
    Journey Medical Corporation
    $DERM
    8/25/2025$13.00Buy
    H.C. Wainwright
    Journey Medical Corporation
    $DERM
    7/30/2025$12.00Buy
    B. Riley Securities
    More analyst ratings

    $ABOS
    $BTTX
    $CACO
    $CNEY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $9,999,990 worth of shares (454,545 units at $22.00) (SEC Form 4)

    4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)

    10/27/25 4:30:38 PM ET
    $VRDN
    Medical Specialities
    Health Care

    Large owner S8 Global Fintech & Regtech Fund bought $71,180 worth of shares (200,000 units at $0.36), increasing direct ownership by 6% to 3,604,845 units (SEC Form 4)

    4 - RYVYL Inc. (0001419275) (Issuer)

    7/17/25 9:00:26 AM ET
    $RVYL
    Professional Services
    Consumer Discretionary

    Large owner S8 Global Fintech & Regtech Fund bought $91,050 worth of shares (114,491 units at $0.80), increasing direct ownership by 3% to 3,504,845 units (SEC Form 4)

    4 - RYVYL Inc. (0001419275) (Issuer)

    7/1/25 9:00:07 AM ET
    $RVYL
    Professional Services
    Consumer Discretionary

    $ABOS
    $BTTX
    $CACO
    $CNEY
    SEC Filings

    View All

    urban-gro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - urban-gro, Inc. (0001706524) (Filer)

    2/25/26 5:00:52 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    SEC Form 6-K filed by CN Energy Group Inc.

    6-K - CN ENERGY GROUP. INC. (0001780785) (Filer)

    2/24/26 5:15:06 PM ET
    $CNEY
    Major Chemicals
    Industrials

    SEC Form S-8 filed by REE Automotive Ltd.

    S-8 - REE Automotive Ltd. (0001843588) (Filer)

    2/24/26 4:01:30 PM ET
    $REE
    Auto Manufacturing
    Industrials

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

    50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dediffe

    2/24/26 7:00:00 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CN Energy Group. Inc. Announces Planned Acquisition of Blessing Logistics Ltd.

    LISHUI, China, Feb. 23, 2026 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ:CNEY, ", CNEY", or the ", Company", )) today announced that it has entered into a Share Purchase Agreement to acquire 100% of the outstanding shares of Blessing Logistics Ltd. ("Blessing Logistics"), an oil trading company incorporated in Alberta. Under the terms of the agreement, the total purchase consideration is USD $2.0 million, expected to be satisfied through the issuance of Class A Ordinary Shares of CNEY. The number of shares to be issued will be determined based on the volume-weighted average price of CNEY's Class A Ordinary Shares for the five consecutive trading days immediately preceding the closing date,

    2/23/26 6:30:00 AM ET
    $CNEY
    Major Chemicals
    Industrials

    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on February 19, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance's common stock to two new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13,

    2/20/26 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Iovance Biotherapeutics upgraded by Citizens with a new price target

    Citizens upgraded Iovance Biotherapeutics from Mkt Perform to Mkt Outperform and set a new price target of $5.00

    2/25/26 7:38:09 AM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Global Partners initiated coverage on NanoViricides

    Alliance Global Partners initiated coverage of NanoViricides with a rating of Buy

    12/16/25 8:59:58 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush reiterated coverage on Viridian Therapeutics with a new price target

    Wedbush reiterated coverage of Viridian Therapeutics with a rating of Outperform and set a new price target of $47.00 from $42.00 previously

    12/10/25 9:29:14 AM ET
    $VRDN
    Medical Specialities
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Kirby Daniel Gordon converted options into 39,996 shares and covered exercise/tax liability with 16,450 shares, increasing direct ownership by 78% to 53,546 units (SEC Form 4)

    4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

    2/12/26 5:00:14 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer & Corp Sec Meisner Derek M exercised 17,756 shares at a strike of $1.85 and sold $53,280 worth of shares (17,756 units at $3.00) (SEC Form 4)

    4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

    1/28/26 7:50:04 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer & Corp Sec Meisner Derek M sold $16,721 worth of shares (8,934 units at $1.87), decreasing direct ownership by 5% to 173,999 units (SEC Form 4)

    4 - Acumen Pharmaceuticals, Inc. (0001576885) (Issuer)

    1/23/26 6:12:54 PM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Leadership Updates

    Live Leadership Updates

    View All

    REE Automotive Announces Appointment of Former Chairman and CEO of Hitachi America, Hicham Abdessamad, as Chairman of the Board of Directors

    TEL AVIV, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) -- REE Automotive Ltd. (NASDAQ:REE), a leading automotive technology company and provider of full by-wire electric vehicle platforms and software-enabled mobility solutions, today announced that Hicham Abdessamad has been appointed Chairman of its Board of Directors, effective December 22, 2025. Mr. Abdessamad succeeds Carlton Rose, who has served as Chairman of the Board since 2023. Mr. Rose will continue to serve as a member of REE's Board of Directors following the transition of the Chair role to Mr. Abdessamad. Mr. Abdessamad has served on REE's Board of Directors since March 29, 2023. He brings deep strategic leadership and extensive

    1/7/26 12:00:00 PM ET
    $REE
    Auto Manufacturing
    Industrials

    RYVYL Highlights Recent Developments for Merger Partner Roundtable that Advance Web3 Platform Traction

    New Strategic Partnerships with The Hockey News and Expansion of Elite Journalist Network to 150+ Former Sports Illustrated Media Professionals SAN DIEGO, CA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ:RVYL) ("RYVYL" or the "Company") today highlighted recent developments achieved by its planned merger partner, Roundtable, including a long-term strategic partnership with The Hockey News and the onboarding of 50 additional Sports Illustrated journalists, expanding its platform to more than 150 former Sports Illustrated media professionals. The Hockey News Partnership & Board Appointment Roundtable recently executed a 10-year strategic partnership agreement with The Hockey News,

    1/7/26 8:00:00 AM ET
    $RVYL
    Professional Services
    Consumer Discretionary

    Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

    NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced George Golumbeski, Ph.D., has joined its Board of Directors as Chairman. Dr. Golumbeski brings more than 30 years of experience in the biopharmaceuticals industry, with extensive expertise in portfolio strategy, strategic collaborations and licensing, and M&A. The addition of Dr. Golumbeski brings the Acumen Board to eight members. "I am very pleased to welcome Dr. Golumbeski to th

    11/10/25 8:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Financials

    Live finance-specific insights

    View All

    Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

    SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to report its fourth quarter and full year 2025 financial results and corporate updates. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/5rbo34au. The live and archived webcast can be accessed in the Investors section of the Company's website, IR.Iovance.com. The archived webcast w

    2/11/26 4:05:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    Third quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quar

    11/12/25 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

    Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain DeliveryTM product candidate in early 2026Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026  Cash, cash equivalents and marketable securities of $136.1 million as of Sept. 30, 2025, expected to support current clinical and operational activities into early 2027 Company to host conference call and webcast today at 8:00 a.m. ET  NEWTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developi

    11/12/25 7:00:00 AM ET
    $ABOS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by DSS Inc.

    SC 13D/A - DSS, INC. (0000771999) (Subject)

    12/12/24 9:56:52 PM ET
    $DSS
    Containers/Packaging
    Consumer Discretionary

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Viridian Therapeutics Inc.

    SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)

    11/14/24 5:53:44 PM ET
    $VRDN
    Medical Specialities
    Health Care

    $ABOS
    $BTTX
    $CACO
    $CNEY
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at urban-gro Inc. on Jun 6

    Urban-gro Inc. saw an interesting insider purchase on June 6, 2024, when Wilks Lewis bought $29,000 worth of shares, acquiring 20,000 units at a price of $1.45 per unit. This transaction increased Lewis' direct ownership by 12% to 184,108 units, as reported in SEC Form 4. Insider transactions like this can provide valuable insights for investors, indicating confidence in the company's future prospects. Analyzing the insider activity surrounding Urban-gro Inc., we can observe several transactions that may reveal patterns or insights. Looking back at previous filings, on September 1, 2023, Wilks Lewis purchased $10,300 worth of shares, acquiring 10,000 units at $1.03 per unit. This

    6/10/24 12:49:49 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary